Digestive and Liver Disease
Volume 42, Issue 12 , Pages 902-907 , December 2010

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

Received 21 January 2010 ,Accepted 27 April 2010.

References 

  1. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174–S184
  2. Suzuki F, Tsubota A, Arase Y. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology. 2003;46:182–189
  3. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47:1473–1482
  4. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495
  5. Lampertico P, Viganò M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414–1449
  6. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000;32:847–851
  7. Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology. 2002;36:219–226
  8. Svicher V, Gori C, Trignetti M, et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol. 2009;50:461–470
  9. Freshwater DA, Dudley T, Cane P, et al. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation. 2008;85:1105–1111
  10. Holomán J, Glasa J. EASL clinical practice guidelines. J Hepatol. 2009;51:821–822
  11. Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006;50:3867–3874
  12. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of virological breakthrough. Hepatology. 2008;48:88–98
  13. Lai MW, Huang SF, Hsu CW, et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther. 2009;14:249–261
  14. Han Y, Huang LH, Miao Liu C, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. J Gastroenterol Hepatol. 2009;24:1417–1423
  15. Rodriguez C, Chevaliez S, Pallier C, et al. Ultra-deep sequencing analysis demonstrates pre-existence of HBV resistance substitution at baseline in patients who subsequently develop clinical resistance. In: CROI. 2010;[Abst N 170lb]
  16. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61:766–768

PII: S1590-8658(10)00164-7

doi: 10.1016/j.dld.2010.04.017

Digestive and Liver Disease
Volume 42, Issue 12 , Pages 902-907 , December 2010

Article Tools

* Image Usage & Resolution